Drug Trial Radar · NCT05153343
Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative
Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
31
Actual
Start
Dec 27, 2021
Primary completion
Nov 29, 2023
Study completion Mar 19, 2025
Sponsor
- Lead sponsor
- Chengdu Zenitar Biomedical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). FM is a dual target inhibitor of JAK2/FLT3.FM has the activity of inhibiting JAK2 signaling pathway, and pharmacodynamics evaluation also confirmed that FM has a good therapeutic effect on the primary splenomegaly model of mice induced by JAK2V617 mutation.Therefore, FM has the potential to treat bone marrow proliferative tumors.The drug is intended to be used in patients with MPN, mainly including medium-risk or high-risk myelofibrosis (FM) (including primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PostPV-MF) and post-primary thrombocythemia myelofibrosis (postET-MF)), Polycythemia vera (PV) and essential thrombocythemia (ET) were the primary causes of thrombocythemia and thrombocythemia. FM has high inhibitory activity against JAK family and FLT3 kinase, suggesting that FM may have a certain therapeutic effect on AML disease. In vitro experiments on the proliferation of JAK2-dependent and Flt3-related tumor cell lines with FM showed that the tumor cell lines had a significant inhibitory effect. The IC50 of half of the tumor cell lines was less than 0.5 μm, which was better than or equal to the similar drugs Ruxolitinib and Fedratinib. The effect of FM on tumor cells from MPN patients indicated that FM has the potential to treat MPN disease. In multiple animal models of bone marrow proliferative tumors with JAK2V617F mutations, FM showed superior efficacy and low toxicity (no obvious VISCAL toxicity) than existing drugs on the market, and the tumor inhibition effect of FM showed a good dose-dependent relationship. Objectives of Study Main Purpose: 1. Tolerance and safety of flonoltinib maleate Tablets tablets in patients with bone marrow proliferative tumors; 2. To observe the possible dose-limiting toxicity(DLT) of flonoltinib maleate tablets in patients with bone marrow proliferative tumors,To determine the maximum tolerated dose(MTD) of flonoltinib maleate tablets,To provide the basis for the recommended dose and design scheme of the later clinical trial. Secondary Purpose: 1. To evaluate the pharmacokinetic characteristics of single and repeated oral administration of flonoltinib maleate tablets in patients with bone marrow proliferative tumors; 2. To evaluate the primary efficacy of single and multiple oral flonoltinib maleate tablets in patients with bone marrow proliferative tumors.
Conditions
- Myeloproliferative Neoplasm (MPN)
- Myelofibrosis,MF
Interventions
flonoltinib 25mgDrug
1 case,The starting dose.Take the medicine once on Day1and Day 5-21,and then 14 days per cycle.
flonoltinib 100mgDrug
Take the medicine once on Day1and Day 5-21,and then 14 days per cycle.
flonoltinib 150mgDrug
Take the medicine once on Day1and Day 5-21,and then 14 days per cycle.
flonoltinib 225mgDrug
Take the medicine once on Day1and Day 5-21,and then 14 days per cycle.
flonoltinib 50mgDrug
Take the medicine once on Day1and Day 5-21,and then 14 days per cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Flonoltinib Maleate Pharmacokinetics (PK):CmaxTime frame: 72hours
- Flonoltinib Maleate Pharmacokinetics (PK):TmaxTime frame: 72hours
- Flonoltinib Maleate Pharmacokinetics (PK):AUC0-72hTime frame: 72hours
- Flonoltinib Maleate Pharmacokinetics (PK):AUC0-∞Time frame: 72hours
- Flonoltinib Maleate Pharmacokinetics (PK):MRTTime frame: 72hours
- Flonoltinib Maleate Pharmacokinetics (PK):VdTime frame: 72hours
- Flonoltinib Maleate Pharmacokinetics (PK):t1/2Time frame: 72hours
- Flonoltinib Maleate Pharmacokinetics (PK):CLz/FTime frame: 72hours
- Flonoltinib Maleate Pharmacokinetics (PK):Vz/FTime frame: 72hours
- Flonoltinib Maleate Pharmacokinetics (PK):KeTime frame: 72hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.